Navigation Links
Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
Date:10/27/2010

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2010 following the close of the market on Thursday, November 4, 2010.

Paul Hamelin, President, and David Gionco, Group Vice President, Chief Financial Officer & Treasurer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on Friday, November 5, 2010 to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 21650025. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on November 5, 2010 through 11:59 p.m. Eastern Time on November 12, 2010 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 21650025.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA(TM) (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Du
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- ... a new specialty pharmaceutical company dedicated to ... innovative injectable and sustained release drug therapies ... medical needs, today announced the acquisition of ... Technology®) platform and associated product pipeline. Acquisition ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... Valeant Pharmaceuticals International, Inc. (NYSE: ... that VPII Escrow Corp., a newly formed wholly owned ... of approximately $3.2 billion aggregate principal amount of senior ... in 2021 and in 2023, with final tranching determined ... the net proceeds from the offering, together with proceeds ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
(Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to ... newly-designed Harley Davidson motorcycle gas tank. A couple of weeks ... idea of taking a split tank motorcycle that had been ... into a work of art. , In October of ... seats that had been dipped in a water transfer printer ...
(Date:6/19/2013)... 2013 Ethigen announced today the US ... service , providing next-generation sequencing (NGS) and rearrangement analysis ... part of an expanded hereditary cancer panel, including full ... links to cancer risk: MLH1, MSH2, MSH6, APC, MUTYH ... FH, FLCN, PDGFRA, and KIT. , The expanded ...
(Date:6/19/2013)... When looking for ways to lose weight ... how to lose belly fat and excess fat in other ... Unnecessary and excess fat storage in these areas can be ... created their hCG diets to specially address these ... loss aids with nutritious meal plans and education on healthy ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Walkingspree, a ... today announced the launch of its new Facebook App. ... motivate and inspire participants to reach their program fitness ... platform , Walkingspree clients are given more tools to ... member profile. , Corporate clients may choose whether or ...
(Date:6/19/2013)... The website HealthNewsWires.com has recently published an informative article ... tips to manage and prevent the condition. , In ... defines insulin resistance as a condition that ... from the bloodstream. Glucose, or blood sugar, is ... systems of the body for normal function. The ...
Breaking Medicine News(10 mins):Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce A New Four Phase Program that Allows Patients to Lose Belly Fat, Thigh Fat and Underarm Fat Easily 2Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2
... highlighted that patients who receive a hematopoietic stem cell transplant ... especially// if they are older during the time of the ... ,A peer-reviewed journal of the American Cancer ... allogeneic HSCT, the comparative risk of a second cancer is ...
... British government has been investing millions of pounds into ... to conduct a massive survey to determine how// accessible ... the intended survey, patients are going to be endowed ... contributing to the doctor’s income. ,The Prime Minister ...
... has planned to kill cats and dogs over fears of ... cull even dogs and cats so as to prevent further ... deadly H5N1 virus at a chicken farm last week. Animal ... extreme measure' because there was no scientific evidence that cats ...
... According to a new study published in January ... short-term structural changes in the cognitive areas of ... journal of the American Cancer Society, the researchers ... months of receiving adjuvant chemotherapy, significant regions of ...
... have observed an alarming trend in the kids, even those between ... teenagers. The physical and// behavioral changes which marks the teenage years ... of 8 to 12; so the sobriquet ‘tweens’, seems to fit ... fancy to own expensive items like cell phones and iPods. The ...
... in Australia to study the attitudes of people towards “tissue ... concerned about the// outcome of storage of tissue samples at ... found that ,most people were wary about biopsy tissue being ... possibly be used to produce human clones in the future. ...
Cached Medicine News:Health News:Stem cell transplant recipients face significant risk of second cancer 2Health News:Britons soon will practise telling GPs how to practice 2Health News:Banking (T)issues : cloning issue surfaces 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: